FDA Approves KADCYLA — Genentech, Inc.

Genentech announced today that the FDA has approved KADCYLA, an antibody-drug conjugate for HER2-positive breast cancer, signaling a strategic expansion in the oncology portfolio that positions the company to capture significant market share from previous treatment standards.